Real-World Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in US Patients with Stage I–III Resected NSCLC Without Known EGFR Mutations: The RESECT Study

• DOI: 10.1007/s40801-025-00487-w
• Publication Date: 2025-05-06T22:14:10Z
• Authors: Jhanelle E. Gray; Rachel J. Salomonsen; Ignacio Diaz Perez; Alice Wang; Ling Cai; Graham Wetherill; Yang Xiao; Claire Fielden; Nefeli Georgoulia

Immunotherapy has altered the treatment landscape for resectable non-small cell lung cancer, increasing complexity of planning. Understanding patterns and outcomes prior to advent immunotherapy can provide context assessing benefit immunotherapies other novel agents. We aimed characterize real-world demographics, clinical characteristics, patterns, patients with early-stage cancer before widespread use. Analyses included from US CancerLinQ Discovery® database diagnosed stage I-III between 2014 2020 without known EGFR mutations who underwent surgical resection within 140 days diagnosis. The primary outcome was by disease stage. 3077 I (n = 1673), II 853), III 551) disease. Most (92.8%, 52.3%, 36.5% I, II, patients) received surgery systemic therapy. Among patients, 7.2%, 44.8%, 46.6% adjuvant therapy only. Of 2.0% 10.2% neoadjuvant only, 0.9% 6.7% both (stage only or perioperative were excluded because low numbers [n 4]). Five-year overall survival rates 73.4%, 61.9%, 50.5% in patients; 5-year relapse-free 35.4%, 23.1%, 14.0%. In an exploratory multivariate analysis, associated improved II-III not evaluable). Adjuvant survival, but patients. alone, though proportion receiving increased Modest 5-year, indicate a need more effective treatments this setting.